HeartRhythm

APRIL 30, 2024

Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrial fibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

Patients with atrial fibrillation (AF) who undergo repeat ablation are more likely to have non pulmonary vein triggers (NPVTs) identified. The influence of these triggers on future recurrence is yet unknown.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation 40

HeartRhythm

APRIL 30, 2024

Patients with persistent atrial fibrillation (PeAF) may need additional ablation approaches on the basis of circumferential pulmonary vein isolation (PVI) to maintain long-term sinus rhythm. However, whether ablation of DZs in addition of PVI is effective in PeAF is unknown.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation 40

Med Page Today

SEPTEMBER 2, 2024

(MedPage Today) -- LONDON -- Pulmonary vein isolation (PVI) produced real short-term improvements for people with atrial fibrillation (Afib or AF), according to the first sham-controlled trial on the subject. Continuous monitoring by implantable.

AFIB 117

AFIB Atrial Fibrillation Ablation Pulmonary 117

DAIC

DECEMBER 29, 2023

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

HeartRhythm

APRIL 30, 2024

While pulmonary vein isolation (PVI) is a key endpoint for atrial fibrillation (AF) ablation, effective strategies for repeat ablation are debated, particularly when PVs are already isolated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) is a novel, nonthermal, cardiac tissue selective ablation modality. To date, radio-frequency (RF) guided high-power-short-duration (HPSD) ablation represents the gold standard for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulmonary vein reconnections (PVRs) remain a concern in atrial fibrillation (AF) ablation. However, the significance of PVR in AF recurrence may differ between patients who undergo additional ablation and those who do not. Eliminating PVRs during redo sessions can lead to favorable rhythm outcomes.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation Outcomes 40

HeartRhythm

APRIL 30, 2024

There are limited effective treatment options for persistent atrial fibrillation (AF) ablation. An epicardial-endocardial approach, combining surgical and catheter convergent radiofrequency (RF) ablation, has shown improved outcomes than an endocardial-only RF strategy.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

HeartRhythm

FEBRUARY 7, 2024

Initial findings from feasibility studies on pulsed field ablation (PFA) in the treatment of atrial fibrillation (AF) indicated high rates of efficacy and pulmonary vein (PV) isolation (PVI) durability upon systematic remapping.

Atrial Fibrillation 75

Atrial Fibrillation Ablation Pulmonary 75

HeartRhythm

APRIL 30, 2024

Pulmonary vein isolation is the cornerstone of catheter ablation of paroxysmal atrial fibrillation. The short-term effects of pulsed field ablation (PFA) on left atrial mechanical function in patients with persistent atrial fibrillation undergoing pulmonary vein and posterior wall isolation has not been investigated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Despite the relative efficacy of ablation, the risk of AF recurrence is substantial, particularly in patients with persistent AF (perAF). At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation.

Pulmonary 64

Pulmonary Ablation Atrial Fibrillation Electrophysiology 64

HeartRhythm

APRIL 30, 2024

Ablation of regions demonstrating spatiotemporal dispersion (SD) has been demonstrated as an alternative strategy beyond pulmonary vein isolation in patients with persistent atrial fibrillation. Occurrence of atrial tachycardia (AT) following ablation remains a limitation of this approach.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Pulmonary 40

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The rate of 12-month freedom from clinical atrial arrhythmia recurrence was 85.1%

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

HeartRhythm

JUNE 24, 2024

Vagal atrial fibrillation (AF) occurs in relatively young people without any organic heart disease, and its onset is caused by changes in autonomic nervous system tone, mainly parasympathetic, such as after eating or drinking alcohol.

Atrial Fibrillation 45

Atrial Fibrillation Ablation Pulmonary Heart Disease 45

HeartRhythm

APRIL 30, 2024

Vein of Marshall ethanol ablation (VOM-EA) as an adjunct to pulmonary vein isolation (PVI) has been reported to improve freedom from atrial fibrillation (AF) and atrial tachycardia (AT).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulmonary vein isolation (PVI) is the mainstem of atrial fibrillation (AF) ablation. However, additional ablation lesions failed to improve it. Recently pulsed-field ablation (PFA) was added to the therapeutic tools for AF ablation, allowing an easier and faster posterior wall isolation (PWI).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

DAIC

FEBRUARY 6, 2024

The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources. and may enroll up to 400 subjects across 20+ centers in the US and Europe.

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

HeartRhythm

JULY 1, 2024

One of the most significant recent advances in developing new technologies for the interventional treatment of atrial fibrillation (AF) has been the introduction of pulsed field ablation (PFA).1

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

Pulmonary vein isolation is a well-established treatment for atrial fibrillation (AF). Despite the increasing evidence in support of catheter ablation for AF, women remain underrepresented in major clinical trials. There is increasing evidence to suggest differences in outcomes between male and female patients.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

Med Page Today

JANUARY 31, 2024

(MedPage Today) -- The FDA approved the Farapulse pulsed field ablation (PFA) system for paroxysmal atrial fibrillation (Afib or AF), Boston Scientific announced on Wednesday. The device won an indication for the isolation of pulmonary veins in.

AFIB 97

AFIB Ablation Atrial Fibrillation Pulmonary 97

HeartRhythm

APRIL 30, 2024

Cryoballoon pulmonary vein isolation (PVI; Cryo-PVI) has comparable results to conventional radiofrequency PVI (RF-PVI) in patients with atrial fibrillation (AF). However, Cryo-PVI using a 28-mm cryoballoon has limitations for wide circumferential PVI or extra-pulmonary vein (PV) trigger (ExPVT) ablations.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrial fibrillation (PeAF) patients. 0.78, p  = .006).

Atrial Fibrillation 75

Atrial Fibrillation Ablation Bicuspid/Mitral Tachycardia 75

HeartRhythm

APRIL 30, 2024

Pulmonary vein (PV) isolation (PVI) adjunctive roofline block using a cryoballoon has been widely performed for patients with atrial fibrillation (AF). However, the efficacy of roof area ablation using a visually guided laser balloon (VGLB) remains to be elucidated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation. We present real-world 5-year follow-up data of AI-guided pulmonary vein isolation.

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

HeartRhythm

APRIL 30, 2024

Pulmonary vein isolation (PVI) using radiofrequency (RF) ablation is an established treatment strategy for atrial fibrillation (AF). Novel high-power short-duration (HPSD) ablation protocols generate an optimized lesion geometry which may translate to an improved ablation efficacy and durability.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40

HeartRhythm

FEBRUARY 5, 2024

Pulsed Field Ablation (PFA), an emerging non-thermal energy modality for ablation procedures, is increasingly used to ablate atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Ablation index (AI)-guided pulmonary vein isolation (PVI) has been widely performed in catheter ablation of atrial fibrillation (AF). Recently, a temperature-controlled ablation catheter (QDOT MICRO, Biosense Webster, Inc) had been introduced, enabling very high-power short-duration (vHPSD) ablation.

Ablation 40

Ablation Pulmonary Atrial Fibrillation 40

HeartRhythm

APRIL 30, 2024

Following pulmonary vein isolation (PVI), about a third of patients have a very late recurrence (VLR) of atrial fibrillation (AF), defined as an AF recurrence after being free of AF for the first year following ablation. Additional data are needed to understand which patients remain at risk for VLR.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Obesity Ablation 40

HeartRhythm

MARCH 6, 2024

Extensive ablation, including posterior wall isolation (PWI) is advocated for radiofrequency ablation (RFA) of persistent atrial fibrillation (peAF) to decrease the high recurrence-rates reported when only pulmonary vein isolation (PVI) is performed.1

Atrial Fibrillation 45

Atrial Fibrillation Ablation Physiology Pulmonary 45

Open Heart

JANUARY 18, 2024

Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.

Atrial Fibrillation 69

Atrial Fibrillation Ablation Pulmonary Arrhythmia 69

HeartRhythm

APRIL 30, 2024

The 1st generation HeartLight laser balloon (LB) ablation is highly effective in achieving pulmonary vein isolation (PVI), and the safety and 12-month efficacy are comparable with paroxysmal atrial fibrillation (PAF) ablation technologies.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Technology 40

HeartRhythm

APRIL 30, 2024

Early recurrence of atrial fibrillation (ERAF) predicts lower 1-year success of cryoballoon (CB) pulmonary vein isolation (PVI). However, the impact of ERAF during the initial 90-day post-ablation blanking period (BP) on VLR is not well understood.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Ablation 40

HeartRhythm

APRIL 30, 2024

Catheter ablation (CA) with pulmonary vein isolation (PVI) is an optimal treatment option in patients with paroxysmal atrial fibrillation (AF). Ablation of additional atrial structures, such as posterior wall (PW) and left atrial appendage has been investigated as a tool to improve procedural efficacy.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary 40

HeartRhythm

APRIL 30, 2024

Pulsed field ablation (PFA) has recently been introduced as a novel routine ablation technology for paroxysmal atrial fibrillation (AF). It is also used as off-label therapy for persistent AF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Technology Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

This prospective study investigated ablative therapy techniques as a treatment of paroxysmal atrial fibrillation (AF). After 12 months of follow-up, there was an 81% freedom of AF in general, which was significantly higher in patients treated with robotic magnetic navigation-guided radiofrequency ablation (RMN-RF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Article 40

HeartRhythm

APRIL 30, 2024

Ablation strategies for persistent atrial fibrillation (PeAF) beyond pulmonary vein isolation remain unclear. Endocardial spatiotemporal dispersion (STD) mapping enabled by artificial intelligence (AI) may reveal AF drivers. Vein of Marshall (VOM) ethanol can improve outcomes in PeAF.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Pulmonary Outcomes 40